Similarly, human epidermal growth factor receptor 2 (HER2) serves not only as a diagnostic and prognostic marker in breast cancer but also as a predictive biomarker guiding targeted therapies such as trastuzumab and pertuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.